Shanzhi Gu

Featured in: Favicon

thelancet.com Favicon

Articles

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Jul 24, 2023 | thelancet.com | Shukui Qin |Stephen Chan |Shanzhi Gu |Yuxian Bai

1. Sung H Ferlay J Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209-2492. Singal AG Lampertico P Nahon P Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020; 72: 250-2613. Llovet JM Ricci S Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-3904. Kudo M Finn RS Qin S et al.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →